Statement Of Cash Flows [Abstract]

Egetis Therapeutics - Filing #5995613

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
3,436,000,000 SEK
3,269,000,000 SEK
Adjustments to reconcile profit (loss) [abstract]
Other adjustments for non-cash items
270,000,000 SEK
177,000,000 SEK
Adjustments to reconcile profit (loss)
886,000,000 SEK
309,000,000 SEK
Interest paid, classified as operating activities
85,000,000 SEK
41,000,000 SEK
Interest received, classified as operating activities
69,000,000 SEK
49,000,000 SEK
Income taxes paid (refund), classified as operating activities
3,000,000 SEK
1,000,000 SEK
Cash flows from (used in) operating activities
2,279,000,000 SEK
2,784,000,000 SEK
Cash flows from (used in) investing activities [abstract]
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
12,000,000 SEK
- SEK
Purchase of property, plant and equipment, classified as investing activities
- SEK
0 SEK
Cash flows from (used in) investing activities
12,000,000 SEK
0 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
3,015,000,000 SEK
3,819,000,000 SEK
Proceeds from borrowings, classified as financing activities
- SEK
1,088,000,000 SEK
Repayments of borrowings, classified as financing activities
77,000,000 SEK
30,000,000 SEK
Payments of lease liabilities, classified as financing activities
25,000,000 SEK
26,000,000 SEK
Cash flows from (used in) financing activities
2,709,000,000 SEK
4,589,000,000 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
418,000,000 SEK
1,804,000,000 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
58,000,000 SEK
48,000,000 SEK
Cash and cash equivalents
3,510,000,000 SEK
3,033,000,000 SEK
1,277,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.